Spectrum PharmaceuticalsInc
Anti-thymocyte globulin, rabbit(Spectrum Pharmaceuticals, Inc)은 Leukemia, Acute 표적 ADC로, Aplastic Anemia; Bone Marrow Failure Syndrome 영역에서 개발·상용화 중입니다. 작용기전: targeting the CD28 pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. PFS: 24. PK: t½ 3 h. 차별점: novel prolonged-release formulation of tacrolimus with enhanced bioavailability.
Leukemia, Acute
Aplastic Anemia; Bone Marrow Failure Syndrome
Recruiting
AAV) is infrequent, with recurrence within weeks of transplantation being even rare
novel prolonged-release formulation of tacrolimus with enhanced bioavailability
targeting the CD28 pathway
immune-mediated destruction of insulin-producing β-cells characterizes type 1 diabetes
apoptosis of B cells in the systemic lymph nodes caused by the ATG administration
biomarkers of immunotherapy response in new-onset type 1 diabetes
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Spectrum PharmaceuticalsInc
Anti-thymocyte globulin, rabbit(Spectrum Pharmaceuticals, Inc)은 Leukemia, Acute 표적 ADC로, Aplastic Anemia; Bone Marrow Failure Syndrome 영역에서 개발·상용화 중입니다. 작용기전: targeting the CD28 pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. PFS: 24. PK: t½ 3 h. 차별점: novel prolonged-release formulation of tacrolimus with enhanced bioavailability.
Leukemia, Acute
Aplastic Anemia; Bone Marrow Failure Syndrome
Recruiting
AAV) is infrequent, with recurrence within weeks of transplantation being even rare
novel prolonged-release formulation of tacrolimus with enhanced bioavailability
targeting the CD28 pathway
immune-mediated destruction of insulin-producing β-cells characterizes type 1 diabetes
apoptosis of B cells in the systemic lymph nodes caused by the ATG administration
biomarkers of immunotherapy response in new-onset type 1 diabetes
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.